Arcutis Biotherapeutics, a leading dermatology company based in Westlake Village, California, has announced that its treatment for seborrheic dermatitis has received approval from the Food and Drug Administration. This news has caused the company’s shares to rise by 18% in after-hours trading, following a slight drop at the close of Friday’s market.
Seborrheic dermatitis is a skin condition that primarily affects the scalp. Arcutis’ Zoryve topical foam has been specifically developed to address this condition. The success of Zoryve has already been demonstrated through its FDA approval for the topical treatment of plaque psoriasis in patients aged six and older. In fact, the cream form of Zoryve generated $8.1 million in net product revenues during the third quarter, according to Arcutis’ latest report.
Looking ahead, Arcutis aims to make the topical foam widely available by the end of next month. This will undoubtedly offer relief and improved quality of life for those suffering from seborrheic dermatitis.
For more information about Arcutis Biotherapeutics and their groundbreaking treatments, please visit their website.
